Literature DB >> 15568026

B and T lymphocyte attenuator regulates T cell activation through interaction with herpesvirus entry mediator.

John R Sedy1, Maya Gavrieli, Karen G Potter, Michelle A Hurchla, R Coleman Lindsley, Kai Hildner, Stefanie Scheu, Klaus Pfeffer, Carl F Ware, Theresa L Murphy, Kenneth M Murphy.   

Abstract

B and T lymphocyte attenuator (BTLA) provides an inhibitory signal to B and T cells. Previously, indirect observations suggested that B7x was a ligand for BTLA. Here we show that BTLA does not bind B7x; instead, we identify herpesvirus entry mediator (HVEM) as the unique BTLA ligand. BTLA bound the most membrane-distal cysteine-rich domain of HVEM, distinct from regions where the ligands LIGHT and lymphotoxin-alpha bound HVEM. HVEM induced BTLA tyrosine phosphorylation and association of the tyrosine phosphatase SHP-2 and repressed antigen-driven T cell proliferation, providing an example of reverse signaling to a non-tumor necrosis factor family ligand. The conservation of the BTLA-HVEM interaction between mouse and human suggests that this system is an important pathway regulating lymphocyte activation and/or homeostasis in the immune response.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15568026     DOI: 10.1038/ni1144

Source DB:  PubMed          Journal:  Nat Immunol        ISSN: 1529-2908            Impact factor:   25.606


  240 in total

1.  BTLA exhibits immune memory for αβ T cells in patients with active pulmonary tuberculosis.

Authors:  Jin-Cheng Zeng; Dong-Zi Lin; Lai-Long Yi; Gan-Bin Liu; Hui Zhang; Wan-Dang Wang; Jun-Ai Zhang; Xian-Jing Wu; Wen-Yu Xiang; Bin Kong; Zheng W Chen; Cong-Yi Wang; Jun-Fa Xu
Journal:  Am J Transl Res       Date:  2014-10-11       Impact factor: 4.060

2.  Forced LIGHT expression in prostate tumors overcomes Treg mediated immunosuppression and synergizes with a prostate tumor therapeutic vaccine by recruiting effector T lymphocytes.

Authors:  Lisa Yan; Diane M Da Silva; Bhavna Verma; Andrew Gray; Heike E Brand; Joseph G Skeate; Tania B Porras; Shreya Kanodia; W Martin Kast
Journal:  Prostate       Date:  2014-11-14       Impact factor: 4.104

3.  BTLA expression contributes to septic morbidity and mortality by inducing innate inflammatory cell dysfunction.

Authors:  Nicholas J Shubin; Chun S Chung; Daithi S Heffernan; Lydea R Irwin; Sean F Monaghan; Alfred Ayala
Journal:  J Leukoc Biol       Date:  2012-03-29       Impact factor: 4.962

4.  Monoclonal antibodies to B and T lymphocyte attenuator (BTLA) have no effect on in vitro B cell proliferation and act to inhibit in vitro T cell proliferation when presented in a cis, but not trans, format relative to the activating stimulus.

Authors:  M Zhang; K Howard; A Winters; S Steavenson; S Anderson; S Smelt; G Doellgast; C Sheelo; J Stevens; H Kim; A Hamburger; A Sein; D J Caughey; F Lee; H Hsu; G Siu; F R Byrne
Journal:  Clin Exp Immunol       Date:  2010-11-16       Impact factor: 4.330

5.  The LIGHT and DARC sides of herpesvirus entry mediator.

Authors:  Tania H Watts; Jennifer L Gommerman
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-13       Impact factor: 11.205

6.  Evolutionarily divergent herpesviruses modulate T cell activation by targeting the herpesvirus entry mediator cosignaling pathway.

Authors:  Timothy C Cheung; Ian R Humphreys; Karen G Potter; Paula S Norris; Heather M Shumway; Bonnie R Tran; Ginelle Patterson; Rochelle Jean-Jacques; Miri Yoon; Patricia G Spear; Kenneth M Murphy; Nell S Lurain; Chris A Benedict; Carl F Ware
Journal:  Proc Natl Acad Sci U S A       Date:  2005-08-30       Impact factor: 11.205

Review 7.  Advances in the development of cancer immunotherapies.

Authors:  Jianjun Gao; Chantale Bernatchez; Padmanee Sharma; Laszlo G Radvanyi; Patrick Hwu
Journal:  Trends Immunol       Date:  2012-09-30       Impact factor: 16.687

Review 8.  SHP-1 and SHP-2 in T cells: two phosphatases functioning at many levels.

Authors:  Ulrike Lorenz
Journal:  Immunol Rev       Date:  2009-03       Impact factor: 12.988

Review 9.  The role of B7 family molecules in hematologic malignancy.

Authors:  Paul Greaves; John G Gribben
Journal:  Blood       Date:  2012-12-06       Impact factor: 22.113

10.  Development of autoimmune hepatitis-like disease and production of autoantibodies to nuclear antigens in mice lacking B and T lymphocyte attenuator.

Authors:  Yoshihiro Oya; Norihiko Watanabe; Takayoshi Owada; Mie Oki; Koichi Hirose; Akira Suto; Shin-Ichiro Kagami; Hiroshi Nakajima; Takashi Kishimoto; Itsuo Iwamoto; Theresa L Murphy; Kenneth M Murphy; Yasushi Saito
Journal:  Arthritis Rheum       Date:  2008-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.